(c) 2024 PillSync.com

Morphine Sulfate 30 MG Extended Release Oral Tablet

1 INDICATIONS AND USAGE Morphine sulfate extended-release tablets are indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve morphine sulfate extended-release for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. Morphine sulfate extended-release is an opioid agonist indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. (1) Limitations of Use (1) Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations, reserve morphine sulfate extended-release for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic.

actavis pharma, inc.


23 minutes ago ROUND YELLOW 271 Morphine Sulfate 30 MG Extended Release Oral Tablet

ROUND YELLOW 271

23 minutes ago ROUND YELLOW 271 Morphine Sulfate 30 MG Extended Release Oral Tablet

271 ROUND YELLOW

16 HOW SUPPLIED/STORAGE AND HANDLING

MORPHINE SULFATE extended-release tablets are available as follows: 15 mg Each round, white to off white, film-coated, unscored tablet debossed with on one side and 270 on the other side contains 15 mg of

MORPHINE SULFATE, USP. Tablets are supplied in bottles of 100 (NDC 0228-4270-11). 30 mg Each round, yellow, film-coated, unscored tablet debossed with on one side and 271 on the other side contains 30 mg of

MORPHINE SULFATE, USP. Tablets are supplied in bottles of 100 (NDC 0228-4271-11). 60 mg Each round, pink, film-coated, unscored tablet debossed with on one side and 311 on the other side contains 60 mg of

MORPHINE SULFATE, USP. Tablets are supplied in bottles of 100 (NDC 0228-4311-11). 100 mg Each round, red, film-coated, unscored tablet debossed with on one side and 323 on the other side contains 100 mg of

MORPHINE SULFATE, USP. Tablets are supplied in bottles of 100 (NDC 0228-4323-11). 200 mg Each capsule-shaped, red, film-coated, unscored tablet debossed with on one side and 347 on the other side contains 200 mg of

MORPHINE SULFATE, USP. Tablets are supplied in bottles of 100 (NDC 0228-4347-11). Store at 25°C (77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Store

MORPHINE SULFATE extended-release tablets securely and dispose of properly [see Patient Counseling Information ( 17 )] . Dispense in a tight, light-resistant container as defined in the USP. logo logo logo logo logo


More pills like ROUND 271












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site